Prevention, Treatment and Cure of HIV Infection

Overview

Journal Nat Rev Microbiol

Specialties Infectious Diseases
Microbiology

Date 2023 Jun 21

PMID 37344551

Authors

Raphael J Landovitz

Hyman Scott

Steven G Deeks

Affiliations

Soon will be listed here.

Abstract

The development of antiretroviral therapy for the prevention and treatment of HIV infection has been marked by a series of remarkable successes. However, the efforts to develop a vaccine have largely failed, and efforts to discover a cure are only now beginning to gain traction. In this Review, we describe recent progress on all fronts - pre-exposure prophylaxis, vaccines, treatment and cure - and we discuss the unmet needs, both current and in the coming years. We describe the emerging arsenal of drugs, biologics and strategies that will hopefully address these needs. Although HIV research has largely been siloed in the past, this is changing, as the emerging research agenda is marked by multiple cross-discipline synergies and collaborations. As the limitations of antiretroviral drugs as a means to truly end the epidemic are becoming more apparent, there is a great need for continued efforts to develop an effective preventative vaccine and a scalable cure, both of which remain formidable challenges.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

HIV-1 adapts to HLA class II-associated selection pressure exerted by CD4 and CD8 T cells.

Alves E, Currenti J, Crawford K, Chopra A, Ram R, Barnett L Sci Adv. 2025; 11(7):eadr4238.

PMID: 39951541 PMC: 11827868. DOI: 10.1126/sciadv.adr4238.

Immune-mediated strategies to solving the HIV reservoir problem.

Kulpa D, Paiardini M, Silvestri G Nat Rev Immunol. 2025; .

PMID: 39948261 DOI: 10.1038/s41577-025-01136-7.

Antibody prophylaxis may mask subclinical SIV infections in macaques.

Gonelli C, King H, Ko S, Fennessey C, Iwamoto N, Mason R Nature. 2025; 639(8053):205-213.

PMID: 39910294 PMC: 11882457. DOI: 10.1038/s41586-024-08500-y.

Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.

Rai M, Blazkova J, Kardava L, Justement J, Shi V, Manning M Nat Med. 2025; 31(2):427-432.

PMID: 39753965 DOI: 10.1038/s41591-024-03357-0.

References

Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L . Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021; 385(7):595-608. PMC: 8448593. DOI: 10.1056/NEJMoa2101016. View

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

Cohen S, Sachdev D, Lee S, Scheer S, Bacon O, Chen M . Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018; . PMC: 6541554. DOI: 10.1016/S2352-3018(18)30288-1. View

Cohen S, Hu X, Sweeney P, Satcher Johnson A, Hall H . HIV viral suppression among persons with varying levels of engagement in HIV medical care, 19 US jurisdictions. J Acquir Immune Defic Syndr. 2014; 67(5):519-27. DOI: 10.1097/QAI.0000000000000349. View

Havlir D, Balzer L, Charlebois E, Clark T, Kwarisiima D, Ayieko J . HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. N Engl J Med. 2019; 381(3):219-229. PMC: 6748325. DOI: 10.1056/NEJMoa1809866. View

Hayes R, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K . Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). N Engl J Med. 2019; 381(3):207-218. PMC: 6587177. DOI: 10.1056/NEJMoa1814556. View

Makhema J, Wirth K, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E . Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med. 2019; 381(3):230-242. PMC: 6800102. DOI: 10.1056/NEJMoa1812281. View

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View

Larmarange J, Diallo M, McGrath N, Iwuji C, Plazy M, Thiebaut R . The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa). J Int AIDS Soc. 2018; 21 Suppl 4:e25128. PMC: 6053480. DOI: 10.1002/jia2.25128. View

10.

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

11.

Liu A, Cohen S, Vittinghoff E, Anderson P, Doblecki-Lewis S, Bacon O . Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2015; 176(1):75-84. PMC: 5042323. DOI: 10.1001/jamainternmed.2015.4683. View

12.

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90. DOI: 10.1016/S0140-6736(13)61127-7. View

13.

Mayer K, Molina J, Thompson M, Anderson P, Mounzer K, De Wet J . Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020; 396(10246):239-254. PMC: 9665936. DOI: 10.1016/S0140-6736(20)31065-5. View

14.

Molina J, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I . On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015; 373(23):2237-46. DOI: 10.1056/NEJMoa1506273. View

15.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

16.

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

17.

Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. PMC: 3001187. DOI: 10.1126/science.1193748. View

18.

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

19.

Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

20.

Baeten J, Hendrix C, Hillier S . Topical Microbicides in HIV Prevention: State of the Promise. Annu Rev Med. 2019; 71:361-377. PMC: 8038211. DOI: 10.1146/annurev-med-090518-093731. View